Attorney Docket No.: 2623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of:

DIETRICH, et al.

Serial No.: 10/505,138

Group Art: 1615

Filed: August 19, 2004

Examiner: SILVERMAN, E.

For:

ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE INGREDIENT AND POLYVINYLPYRROLIDON AS EXCIPIENT

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- Transmittal letter; 1)
- 2) Response and Amendment;
- 3)
- Appendix A; and Check No. 1317 in the amount of \$1400.00 for excess 4) claims fee.

Please charge any required fee, or credit any overpayment, in connection with this matter to deposit Account No. 14-0112.

Date: December 1, 2005

NATH & ASSOCIATES PLLC

1030 Fifteenth Street, N.W.

Sixth Floor

Washington, D.C. 20005-1503

Tel: (202) 775-8383 Fax: (202) 775-8396

JBG/SMM\ROA.TL.doc

Respectfully submitted,

Gary M. Nath

Reg. No. 26,965

Joshua B. Goldberg

Reg. No. 44,126

Sheldon M. McGee Reg. No. 50,454

Customer No. 34375

DEC 0 1 2005 W

Attorney Docket No.: 26230

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DIETRICH, et al.

Serial No.: 10/505,138 Group Art: 1615

Filed: August 19, 2004 Examiner: SILVERMAN, E.

For: ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE INGREDIENT AND POLYVINYLPYRROLIDON AS EXCIPIENT

RESPONSE AND AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is in response to the Office Action dated September 1, 2005. The three-month shortened statutory period for response expires on December 1, 2005. Accordingly, this response should be considered timely filed.

AMENDMENT

IN THE CLAIMS:

Please cancel claims 1-17 without prejudice to or disclaimer of the subject matter contained therein and add new claims 18-65 as outlined in Appendix A, attached herewith.

...

12/02/2005 SZEWDIE1 00000120 10505138

01 FC:1202

1400.00 OP